Zynex Inc
Zynex Inc. is a U.S.-based medical device company headquartered in Englewood, Colorado, focused on electrotherapy and pain management products. Through its operating subsidiaries, it sells and leases devices and supplies used in home and clinical settings, and it also owns a patient-monitoring technology platform developed through its ZMS subsidiary.
Tilikausi 2024 · muutos edellisvuodesta
Kehitys 2019–2024
Liiketoiminta
Osuus liikevaihdostaPain-management and rehabilitation devices sold or leased to patients and providers.
Recurring consumables used with electrotherapy products, mainly electrodes and batteries.
Branded support and therapy products sold alongside the core device portfolio.
Laser-based noninvasive monitoring products under development through ZMS/Kestrel.
Tuotteet
Raportoitu · osuus liikevaihdosta- Public Utilities Inventory Supplies69,0 %
- Devices31,0 %
Lähde: 10-K/A FY2024, yhtiön tuotelinjoittain raportoima liikevaihto (SEC XBRL). Osuudet on laskettu näytetyistä riveistä ja ne summautuvat 100 %:iin.
Asiakkaat
Zynex sells primarily into the U.S. healthcare market, with reimbursement-driven demand from patients using electrotherapy products and the providers or payers that support those prescriptions. Its products are used for pain management, rehabilitation, and patient monitoring, so customer demand depends on clinical adoption, insurance reimbursement, and durable repeat supply usage.
Patients who receive electrotherapy devices and recurring supplies for chronic pain or rehabilitation.
Third-party payers that determine reimbursement levels and claim acceptance for device and supply revenue.
Clinicians that drive patient placement by recommending Zynex devices and related supplies.
Potential partners for NiCO and HemeOx who could help bring monitoring technologies to market.
Strategia
Zynex’s core strategy centers on selling and supporting electrotherapy devices and recurring supplies through its U.S. commercial platform. It is also seeking to advance or monetize its noninvasive monitoring technologies through strategic partnerships rather than independent commercialization, which changes how the company may develop and fund that pipeline.
Recurring supplies and device placements are the main commercial engine of the business.
The company depends on efficient patient acquisition and prescription conversion.
Strategic partners may provide regulatory, commercial, and funding support for NiCO and HemeOx.
Maantiede
Zynex is headquartered in Englewood, Colorado and conducts most of its operations through U.S.-based subsidiaries. The business is primarily exposed to the United States healthcare reimbursement system, while its monitoring technology efforts also create exposure to regulatory and commercialization pathways outside the core device business.
Riskit
Zynex is exposed to reimbursement, payer, and claim-processing risk because a large part of its revenue depends on third-party payment decisions and patient collections. It also faces development, regulatory, and partnership risk in its monitoring technologies, plus supply-chain and tariff exposure for components sourced outside the U.S.
- Third-party payer reimbursement disruptionVaikutus: KorkeaTodennäköisyys: Korkea
Revenue depends on insurer payment decisions, claim processing, and patient eligibility.
Kohdistuu: Core device and supply revenue
- Strategic partnership execution riskVaikutus: KorkeaTodennäköisyys: Korkea
NiCO and HemeOx may require external partners to reach market and generate value.
Kohdistuu: Monitoring technology pipeline
- Regulatory and litigation riskVaikutus: KeskitasoTodennäköisyys: Korkea
SEC requests and other legal matters can create expense, uncertainty, and reputational damage.
Kohdistuu: Corporate and operating risk
- Tariffs and import cost inflationVaikutus: KeskitasoTodennäköisyys: Kohtalainen
Manufactured products and components sourced outside the U.S. may become more expensive.
Kohdistuu: Cost of revenue and gross margin
Kirjanpito
Harkinnanvaraiset erätReported revenue depends on estimated reimbursement reductions and collectability assumptions.
Vaikutus: Can materially change net revenue and receivables
Insurance denials and resubmitted claims require ongoing estimation.
Vaikutus: Affects revenue, accounts receivable, and cash conversion
Kestrel-related assets may be written down if commercialization prospects weaken.
Vaikutus: Can create large non-cash charges
Quarterly tax expense can be distorted by valuation allowance changes and stock-based items.
Vaikutus: Affects effective tax rate and net income
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Zymeworks Inc.
ZYME · Pharmaceutical Preparations
Zicix Corp
ZICX · Services-Advertising
Zicix Corp is a U.S.-based services and trading company organized around product sales and cloud services.
ZyVersa Therapeutics, Inc.
ZVSA · Pharmaceutical Preparations
Neuraxis, INC
NRXS · Electromedical & Electrotherapeutic Apparatus
Neuraxis, INC is a U.S.-based medical device company focused on neuromodulation therapies for pediatric and adult patients.
Pulse Biosciences, Inc
PLSE · Surgical & Medical Instruments & Apparatus
Pulse Biosciences is a U.S.-based medical technology company focused on developing and commercializing nonthermal pulsed field ablation systems.
Streamex Corp.
STEX · Security & Commodity Brokers, Dealers, Exchanges & Services
Päivitetty: 24.9.2026